Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF (POMINC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01644110|
Recruitment Status : Recruiting
First Posted : July 18, 2012
Last Update Posted : November 8, 2018
|Condition or disease||Intervention/treatment||Phase|
|Primary Myelofibrosis Secondary Myelofibrosis PMF SMF Post-PV MF Post-ET MF||Drug: INCB018424/CC-4047||Phase 1 Phase 2|
The proposed study is an open-label, single-arm, Phase-Ib/II trial to assess the efficacy of oral drug combination ruxolitinib and pomalidomide in primary and secondary MF patients. Dosages of the drugs are derived from previous Phase-I/II studies; ruxolitinib treatment will be started at 10 mg twice daily, whereas the dose of pomalidomide will be 0.5 mg once daily.
Dose reductions and discontinuations will be allowed in case of myelosuppressive effects.
Intra-patient dose escalation will be permitted for ruxolitinib to optimize efficacy of the therapeutic regimen; pomalidomide will be given in a permanent dosage of 0.5mg per day.
Treatment response will be evaluated continuously after each treatment cycle (1 cycle = 28 days) according to the IWG-MRT criteria expanded by the response criterion RCT-independency.
In case of progressive disease study therapy will be stopped; In patients showing response or stable disease, continuous therapy within the study is intended for a maximum of 12 treatment cycles; After completion of 12 treatment cycles, therapy can be continued if a measurable benefit of treatment is evident. This extension has to be discussed between the local and the principle investigator. Conditions leading to patient withdrawal from the study are detailed in the protocol "PATIENT WITHDRAWAL FROM STUDY PARTICIPATION".
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||72 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary Myelofibrosis|
|Study Start Date :||August 2013|
|Estimated Primary Completion Date :||May 2019|
|Estimated Study Completion Date :||May 2022|
ruxolitinib treatment will be started at 10 mg twice daily, whereas the dose of pomalidomide will be 0.5 mg once daily.
For all patients the starting dose of ruxolitinib in this trial is 10mg twice daily po; pomalidomide will be administered at a permanent dose of 0.5 mg po once daily.
- Best response rate within 12 treatment cycles according to the IWG-MRT criteria (including CR, PR, CI) and red cell transfusion (RCT) independency according to Gale et al 2010 and 2011). [ Time Frame: one year ]Best response rate within 12 treatment cycles according to the IWG-MRT
- Overall safety profile of ruxolitinib and pomalidomide combination observed during treatment, as well as cumulative incidence of leukemic transformation [ Time Frame: one year ]Overall safety profile of ruxolitinib and pomalidomide combination characterized by type, frequency, severity (graded using the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] Version 3.0), timing and relatedness of adverse events (AEs) and laboratory abnormalities observed during treatment, as well as cumulative incidence of leukemic transformation
- Progression-free survival [ Time Frame: three years ]Progression-free survival
- duration of response [ Time Frame: three years ]duration of response
- overall survival [ Time Frame: three years ]overall survival
- Quality of life assessed by the Myeloproliferative Neoplasm Symptom [ Time Frame: three years ]Quality of life assessed by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF Protocol 5/25/11), change in ECOG performance status from study entry to each visit where the variable is measured.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01644110
|Contact: Konstanze Doehner, MD||0049731500 ext email@example.com|
|Contact: Frank Stegelmann, MD||0049731500 ext firstname.lastname@example.org|
|University of Ulm||Recruiting|
|Ulm, Germany, 89081|
|Contact: Konstanze Doehner, MD email@example.com|
|Principal Investigator: konstanze Doehner, Md|
|Principal Investigator:||Konstanz Doehner, MD||University of Ulm|